AR099960A1 - Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria - Google Patents
Procedimientos y composición farmaceutica para inducir una respuesta inmunitariaInfo
- Publication number
- AR099960A1 AR099960A1 ARP150101025A ARP150101025A AR099960A1 AR 099960 A1 AR099960 A1 AR 099960A1 AR P150101025 A ARP150101025 A AR P150101025A AR P150101025 A ARP150101025 A AR P150101025A AR 099960 A1 AR099960 A1 AR 099960A1
- Authority
- AR
- Argentina
- Prior art keywords
- common
- adjuvant
- composition
- antigen
- rts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un procedimiento para inducir una respuesta inmunitaria en un sujeto humano que comprende la administración de una primera composición inmunógena que comprende uno o más antígenos y un primer coadyuvante al sujeto seguido de la administración de una segunda composición inmunógena que comprende uno o más antígenos y un segundo coadyuvante al sujeto, en el que la primera y segunda composición tienen al menos un antígeno en común, en el que el primer y segundo coadyuvante comprende un agonista de TLR y/o una saponina inmunológicamente activa y tienen al menos uno de estos dos componentes en común y en el que el segundo coadyuvante contiene una cantidad del componente común que menor el primer coadyuvante, y/o el antígeno común es RTS,S y la segunda composición contiene una cantidad de RTS,S menor que la primera composición, con la condición de que la primera y segunda composiciones no comprendan RTS,S y QS21 y 3D-MPL asociado con una formulación de emulsión de aceite en agua. Reivindicación 9: El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que el primer y segundo coadyuvante comprenden 3D-MPL y QS21 en una formulación liposomal. Reivindicación 17: El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que el antígeno común es un antígeno de Plasmodium, tal como un antígeno de P. falciparum o de P. vivax. Reivindicación 18: El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que el antígeno común es una proteína del circunsporozoíto o un fragmento inmunógeno o variante del mismo. Reivindicación 26: Una composición inmunógena para su uso en un procedimiento para inducir una respuesta inmunitaria en un sujeto humano, en el que el procedimiento comprende la administración de una primera composición inmunógena que comprende uno o más antígenos y un primer coadyuvante al sujeto seguido de la administración de una segunda composición inmunógena que comprende uno o más antígenos y un segundo coadyuvante al sujeto, en el que la primera y segunda composición tienen al menos un antígeno en común y el primer y segundo coadyuvante comprenden un agonista de TLR y/o una saponina inmunológicamente activa y tienen al menos uno de estos dos componentes en común y en el que el segundo coadyuvante contiene una cantidad del componente común menor que el primer coadyuvante, y/o el antígeno común es RTS,S y la segunda composición contiene una cantidad de RTS,S menor que la primera composición, con la condición de que la primera y segunda composiciones no comprendan RTS,S y QS21 y 3D-MPL asociado con una formulación de emulsión de aceite en agua.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1405921.6A GB201405921D0 (en) | 2014-04-02 | 2014-04-02 | Novel methods for inducing an immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099960A1 true AR099960A1 (es) | 2016-08-31 |
Family
ID=50737873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101025A AR099960A1 (es) | 2014-04-02 | 2015-04-06 | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10624961B2 (es) |
| EP (2) | EP3125929B8 (es) |
| JP (2) | JP6645982B2 (es) |
| KR (2) | KR20230075525A (es) |
| CN (2) | CN106456739A (es) |
| AR (1) | AR099960A1 (es) |
| AU (1) | AU2015239025B2 (es) |
| BE (1) | BE1022355B1 (es) |
| BR (2) | BR112016022463A2 (es) |
| CA (2) | CA2943711A1 (es) |
| EA (1) | EA037405B1 (es) |
| ES (2) | ES2961840T3 (es) |
| GB (1) | GB201405921D0 (es) |
| IL (1) | IL247493B (es) |
| MX (3) | MX2016012982A (es) |
| SG (1) | SG11201607086QA (es) |
| WO (2) | WO2015150567A1 (es) |
| ZA (1) | ZA201605955B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| IE87414B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| EP3717001A1 (en) | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Saponin purification |
| CN114080393A (zh) | 2019-06-05 | 2022-02-22 | 葛兰素史克生物有限公司 | 皂苷纯化 |
| CN113125756B (zh) * | 2020-07-15 | 2022-10-25 | 南京岚煜生物科技有限公司 | 抗体标准品赋值和抗原中和当量确定的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US152200A (en) * | 1874-06-16 | Improvement in garters | ||
| US1002607A (en) * | 1905-08-28 | 1911-09-05 | John Willard Taylor | Paper pulley. |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US8232255B2 (en) | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| RS52187B (en) | 2004-10-14 | 2012-10-31 | Crucell Holland B.V. | Vaccines for the induction and stimulation of the immune response for malaria |
| PL2426141T3 (pl) * | 2005-04-29 | 2015-02-27 | Glaxosmithkline Biologicals Sa | Sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2368568A1 (en) * | 2006-11-01 | 2011-09-28 | Immport Therapeutics, INC. | Compositions and methods for immunodominant antigens |
| CL2008000611A1 (es) * | 2007-03-02 | 2008-09-05 | Glaxosmithkline Biolog Sa | Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica |
| TW200908994A (en) * | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2009273133B2 (en) * | 2008-07-25 | 2014-06-05 | Glaxo Group Limited | Novel compositions and methods |
| EA201100070A1 (ru) * | 2008-07-25 | 2011-10-31 | Глаксо Груп Лимитед | Туберкулезный белок rv2386c, композиции и их применения |
| ES2602430T3 (es) * | 2008-07-25 | 2017-02-21 | Glaxosmithkline Biologicals S.A. | Polipéptidos, polinucleótidos y composiciones para uso en el tratamiento de tuberculosis latente |
| SI2528621T1 (sl) * | 2010-01-27 | 2017-01-31 | Glaxosmithkline Biologicals S.A., | Modificirani tuberkolozni antigeni |
| SG190731A1 (en) * | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
| US20170056345A1 (en) * | 2014-02-18 | 2017-03-02 | Stc.Unm | Booster drug therapy for mycobacterium infections |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| US10004793B2 (en) * | 2014-04-24 | 2018-06-26 | Statens Serum Institut | M.tuberculosis vaccines |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
-
2015
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 CA CA2943711A patent/CA2943711A1/en not_active Abandoned
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/en active Active
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/en active Active
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 CA CA2943007A patent/CA2943007C/en active Active
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 KR KR1020237017095A patent/KR20230075525A/ko not_active Application Discontinuation
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/en active Application Filing
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active IP Right Cessation
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/en active Application Filing
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja active Active
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
-
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
-
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
| CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
| CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
| EA201790507A1 (ru) | Способы и композиции для усиления иммунных ответов | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
| MX2017006744A (es) | Composiciones adyuvantes y metodos relacionados. | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| BR112014012184A2 (pt) | vacina de malária | |
| AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene | |
| BR112017028052A2 (pt) | peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina | |
| MX2022000525A (es) | Vacunas contra la ehrlichia y composiciones inmunogenicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |